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     INTRODUCTION 
Preterm labor is defined as delivery occurring 
between 22 and 36+6 weeks of gestation, with 
gestational age determined based on the 1st day of 
the last menstrual period and fetal scanning 
performed in the 1st trimester.1 About 15 million 
babies are born prematurely each year, and this 
number steadily increases. Complications of preterm 
labor are the leading cause of death in infants under 
5 years of age. According to the WHO, the rates of 
preterm labor range from 5 to 18% of the number of 
the newborns in 184 countries.2 Clinical symptoms 
that determine the true onset of labor are the same 
regardless of gestational age and are manifested as 
structural changes in the cervix and the onset of 
regular labor activity. Cervical changes include 
dilatation of internal orifice, shortening, softening, 
and centralization of the cervix. Cervical changes in 
the started PL occur within several hours, which 
distinguishes them from the cervical ripening 
process, which occurs over days or even weeks.1  
 
The criteria for diagnosing the threatened preterm 
labor are manifested as irregular pain in the lower 
abdomen and lumbar region. Uterine hypertonus, 
shortening of the cervix, and opening of the external 
orifice are objectively detected. The started preterm 
labor is accompanied by lower abdominal pain, 






the shortened, softened, and often dilated cervix, 
mucosal or mucosal-serous secretions from the 
genital tracts suggestive of cervical ripening. 
Amniotic fluid may discharge prematurely. In a few 
countries, nifedipine and atosiban are recommended 
as first-line tocolytic therapy.1 Nifedipine and 
atosiban have comparable efficacy in prolonging 
pregnancy for up to 7 days. Compared with β-
agonists, nifedipine is associated with improved 
neonatal outcome, but long-term data are not 
available to date. A meta-analysis showed no 
significant differences between atosiban and 
nifedipine in prolonging pregnancy. However, 
atosiban was associated with fewer maternal side 
effects than nifedipine.3 The use of nifedipine and 
atosiban within 48 hours in pregnant women at risk 
of preterm labor is associated with similar perinatal 
outcomes.4 A study showed showed that infants born 
before 32 weeks of gestation after tocolytics use had 
a high incidence of craniocerebral injury. No 
significant differences were found in the organic 
brain lesion between neonates whose mothers 
received nifedipine and neonates who received 
atosiban.5 Compared with β-adrenergic agonists the 
use of atosiban was associated with a significantly 
lower incidence of adverse events such as 
tachycardia, palpitations, vomiting, headache, 
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hypokalemia, and fetal tachycardia.6 In another 
study, atosiban was found to be a more effective 
tocolytic than hexoprenaline in the treatment of 
threatened preterm labor. A study showed that 
atosiban prolonged pregnancy by 48 hours or more 
in 71.9% of pregnant women.7 In another study, the 
comparison of nifedipine and fenoterol showed the 
same latent period in both groups. More side effects 
were reported in the fenoterol group. The economic 
evaluation did not reveal a significant difference in 
cost savings between the groups receiving either 
drug. Neither clinical nor economic superiority of 
either of the two drugs was demonstrated in the 
study.8 A randomized study showed a difference 
between oral and sublingual use of nifedipine. The 
time required for tocolysis was significantly shorter 
with sublingual nifedipine. Sublingual nifedipine 
was also more effective than oral nifedipine in 
stopping preterm labor within 90 minutes.9 Other 
randomized study demonstrated the efficacy of 
nifedipine in combination with sildenafil citrate with 
fewer deliveries within 7 days of hospitalization and 
fewer admissions in neonatal intensive care units, 
fewer early preterm deliveries, and increased birth 
weights.10 Comparison of nifedipine with terbutaline 
in other study showed a similar tocolytic effect of the 
drugs. However, nifedipine was associated with 
fewer side effects.11  
 
Atosiban is also preferred over β-adrenergic agonists 
and drugs with similar effects. The prolongation of 
pregnancy by 48 hours was significantly higher in the 
atosiban group than in the ritodrine group, while the 
prolongation of pregnancy by 7 days was similar in 
both groups. The incidence of side effects in 
pregnant women was higher in the ritodrine group 
than in the atosiban group, but the prevalence of 
abnormal fetal heart rhythm was not statistically 
significantly different. Both perinatal mortality and 
prevalence of neonatal asphyxia were significantly 
lower in the atosiban group. Perinatal mortality and 
prevalence of neonatal pneumonia were also lower in 
the atosiban group when using the drug at 
gestational age less than 28 weeks. Regardless of the 
drug initiation time, there were no significant 
differences between the atosiban and ritodrine 
groups in the cases of neonatal asphyxia, acute 
respiratory distress syndrome, neonatal 
craniocerebral injury, or neonatal sepsis.12 A 
randomized, controlled study compared the efficacy 
of the nicorandil, a potassium channel blocker, and 
nifedipine, a calcium channel blocker, for tocolysis in 
preterm labor. Nicorandil was comparable to 
nifedipine in terms of pregnancy prolongation by 48 
hours, 7 days and up to 37 weeks of gestation. Nausea 
and vomiting, maternal tachycardia, and fetal 
tachycardia were significantly more common in 
women treated with nicorandil. Headaches were 
significantly more common in women treated with 
nifedipine. There was no difference in neonatal 
outcome between the two groups.13 To date, 
indomethacin remains a second line tocolytic, but 
studies have shown a low safety profile. A meta-
analysis showed the probability of pregnancy 
prolongation by 48 hours was highest in 
prostaglandin inhibitors versus placebo, followed by 
magnesium sulfate, calcium channel blockers, β-
adrenergic agonists, and atosiban. Compared to 
placebo, the side effects requiring drug switching 
were significantly higher for β-adrenergic agonists, 
magnesium sulfate, and calcium channel.14 Studies of 
progesterone use in successful tocolysis are 
controversial and require further investigation. 
Maintenance vaginal progesterone tocolysis is 
associated with significant prolongation of 
pregnancy and lower neonatal sepsis.15 Another 
study also showed benefits of vaginal progesterone 
in pregnancy prolongation after successful tocolysis 
with atosiban.16 A systematic review by showed that 
women treated with 17-alpha hydroxyprogesterone 
caproate had significantly later gestational age at 
delivery and higher neonatal weights compared to 
controls. Other secondary outcomes, including 
neonatal mortality, neonatal intensive care unit 
admission rate, neonatal respiratory distress 
syndrome, bronchopulmonary dysplasia, 
intraventricular hemorrhage, necrotizing 
enterocolitis, and neonatal sepsis, were similar in 
both groups.17 In contrast, other study showed that 
injections of 17-alpha-hydroxyprogesterone caproate 
did not significantly prolong pregnancy in women 
with preterm labor after tocolysis.18 Two studies 
demonstrated the efficacy of prolonged progesterone 
tocolysis compared to nifedipine with better 
neonatal outcomes and fewer side effects.19,20 A study 
conducted in India showed that oral micronized 
progesterone significantly prolonged pregnancy.21 A 
systematic review including 16 randomized 
controlled trials showed that the preterm labor rate 
at less than 37 weeks of gestation decreased and 
gestational age increased when women received 
progestogens compared to placebo or no 
treatment.22 Another study showed that 
progesterone was ineffective in the prevention of PL 
after successful tocolysis.23 Both the development of 
new drugs for tocolysis and the study of 
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combinations of the available tocolytics are 
promising. It is not clear whether a combination of 
tocolytic drugs in preterm labor is more effective in 
women and/or neonates because of the lack of large 
studies of combination tocolytic regimens. Further 
trials are needed before specific conclusions can be 
drawn about the use of combination tocolytic 
therapy in preterm labor. 
 
CONCLUSION 
The analysis of available literature showed that 
preterm labor is the leading cause of neonatal 
morbidity, mortality, and long-term consequences. 
Prevention and treatment of preterm labor remain a 
challenge in modern obstetrics. The accumulated 
domestic and foreign experience suggests that 
despite the increasing range of tocolytic agents, there 
are currently no more effective agents to suppress 
the contractility of the uterus than oxytocin receptor 
agonists and calcium channel blockers. As for 
neonatal outcomes, it is difficult to select the 
preferred drug because all tocolytics have a similar 
spectrum of outcomes for the fetus and newborn. 
Many studies suggest that clinicians should use a 
tocolytic that has produced the best results with the 
least adverse effects for the mother/newborn. It is 
necessary to continue clinical trials in order to select 
an effective, and most importantly safe, therapy for 
threatened preterm labor. 
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